Inhibikase Therapeutics (IKT) Equity Ratio (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Equity Ratio for 6 consecutive years, with 0.92 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio rose 855.51% to 0.92 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.92, a 855.51% increase, with the full-year FY2024 number at 0.96, up 27.14% from a year prior.
- Equity Ratio was 0.92 for Q3 2025 at Inhibikase Therapeutics, up from 0.9 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.96 in Q4 2024 to a low of 0.12 in Q3 2024.
- A 5-year average of 0.79 and a median of 0.88 in 2022 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: plummeted 114.43% in 2024, then skyrocketed 855.51% in 2025.
- Inhibikase Therapeutics' Equity Ratio stood at 0.9 in 2021, then decreased by 6.74% to 0.84 in 2022, then decreased by 10.29% to 0.76 in 2023, then grew by 27.14% to 0.96 in 2024, then decreased by 4.81% to 0.92 in 2025.
- Per Business Quant, the three most recent readings for IKT's Equity Ratio are 0.92 (Q3 2025), 0.9 (Q2 2025), and 0.91 (Q1 2025).